Small Molecule Chaperones for the Treatment of Gaucher Disease and GBA1 -Associated Parkinson Disease

Frontiers in Cell and Developmental Biology
Tae-Un HanEllen Sidransky

Abstract

Parkinson disease, the second most common movement disorder, is a complex neurodegenerative disorder hallmarked by the accumulation of alpha-synuclein, a neural-specific small protein associated with neuronal synapses. Mutations in the glucocerebrosidase gene (GBA1), implicated in the rare, autosomal recessive lysosomal disorder Gaucher disease, are the most common known genetic risk factor for Parkinson disease. Insights into the inverse relationship between glucocerebrosidase and alpha-synuclein have led to new therapeutic approaches for the treatment of Gaucher disease and GBA1-associated Parkinson disease. Unlike the current drugs used to treat Gaucher disease, which are highly expensive and do not cross the blood-brain-barrier, new small molecules therapies, including competitive and non-competitive chaperones that enhance glucocerebrosidase levels are being developed to overcome these limitations. Some of these include iminosugars, ambroxol, other competitive glucocerebrosidase inhibitors, and non-inhibitory chaperones or activators that do not compete for the active site. These drugs, which have been shown in different disease models to increase glucocerebrosidase activity, could have potential as a therapy for Gaucher d...Continue Reading

References

Aug 28, 1997·Nature·M G SpillantiniM Goedert
Dec 21, 2000·Current Rheumatology Reports·G M PastoresH Firooznia
Nov 16, 2002·Proceedings of the National Academy of Sciences of the United States of America·Anu R SawkarJeffery W Kelly
Oct 7, 2004·Molecular Genetics and Metabolism·Ellen Sidransky
Jul 28, 2006·Chembiochem : a European Journal of Chemical Biology·Philippe CompainNaoki Asano
Dec 26, 2006·Nature Chemical Biology·Raquel L LiebermanGregory A Petsko
Dec 11, 2008·Annals of Neurology·Raphael SchiffmannAshok Vellodi
Jul 7, 2009·The Journal of Biological Chemistry·Gustavo H B MaegawaDon J Mahuran
Oct 16, 2009·Chembiochem : a European Journal of Chemical Biology·Zhuo LuanYoshiyuki Suzuki
Oct 23, 2009·The New England Journal of Medicine·E SidranskyS G Ziegler
Oct 1, 2010·Blood Cells, Molecules & Diseases·N GuptaE Sidransky
Nov 11, 2010·Chembiochem : a European Journal of Chemical Biology·Zhuo LuanYoshiyuki Suzuki
May 3, 2011·PloS One·Ying SunGregory A Grabowski
Jun 10, 2011·The Journal of Biological Chemistry·Thai Leong YapJennifer C Lee
Dec 14, 2011·Proceedings of the National Academy of Sciences of the United States of America·Jie LuZhengping Zhuang
Dec 15, 2011·The Journal of Biological Chemistry·Ying SunGregory A Grabowski
Jun 12, 2012·Brain & Development·Zhuo LuanKousaku Ohno
Oct 5, 2012·Annals of Neurology·Matthew E GeggAnthony H V Schapira
Oct 20, 2012·Lancet Neurology·Ellen Sidransky, Grisel Lopez
Oct 23, 2012·Blood Cells, Molecules & Diseases·Ari ZimranDeborah Elstein
Nov 20, 2012·Blood Cells, Molecules & Diseases·Inna Bendikov-BarMia Horowitz
Jan 2, 2013·Proceedings of the National Academy of Sciences of the United States of America·Chunzhang YangZhengping Zhuang
Apr 17, 2013·JAMA Neurology·Michael A NallsEllen Sidransky
Jan 31, 2014·Brain : a Journal of Neurology·Karen E MurphyGlenda M Halliday
Feb 28, 2014·Brain : a Journal of Neurology·Alisdair McNeillAnthony H V Schapira
Jun 13, 2014·Science Translational Medicine·Elma AflakiEllen Sidransky
Jul 20, 2014·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Franziska RichterMarie-Françoise Chesselet
Oct 30, 2014·Brain : a Journal of Neurology·Ianai FishbeinRobert L Nussbaum
Dec 2, 2014·Molecular Genetics and Metabolism·Karin WeissEllen Sidransky
Sep 9, 2015·Drug Design, Development and Therapy·Lunawati L Bennett, Kelsey Turcotte
Feb 4, 2016·Proceedings of the National Academy of Sciences of the United States of America·Joseph R MazzulliDimitri Krainc
Apr 5, 2016·Annals of Clinical and Translational Neurology·Aya NaritaYoshiyuki Suzuki
Jul 15, 2016·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Elma AflakiEllen Sidransky
Jul 23, 2016·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Joseph R MazzulliDimitri Krainc
Aug 20, 2016·Scientific Reports·Alvaro Sanchez-MartinezAnthony H V Schapira
Nov 20, 2016·Annals of Neurology·Anna Migdalska-RichardsAnthony H V Schapira

❮ Previous
Next ❯

Citations

Jan 24, 2021·Molecular Genetics and Metabolism·Emily C DaykinEllen Sidransky
Mar 25, 2021·Expert Review of Hematology·Shoshana Revel-VilkAri Zimran
Dec 15, 2021·The European Journal of Neuroscience·Wenjing ShenYingzhu Chen

❮ Previous
Next ❯

Methods Mentioned

BETA
enzyme replacement therapy

Related Concepts

Related Feeds

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Alpha-Synuclein Aggregation (MDS)

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Related Papers

Molecular Neurodegeneration
Jenny DoEllen Sidransky
Journal of Medical Genetics
O Goker-AlpanEllen Sidransky
Proceedings of the National Academy of Sciences of the United States of America
Anthony H V Schapira, Matthew E Gegg
© 2022 Meta ULC. All rights reserved